BMS-223131

BMS-223131 (Compound 1) is a potent maxi-K potassium channel opener. BMS-223131 has a strong inhibitory effect on the CYP2C9 enzyme (IC50 = 1.7 μM) and also shows varying degrees of inhibition on other common CYP enzymes such as CYP1A2, CYP2C19, CYP2D6, and CYP3A4. BMS-223131 can enhance the outward current mediated by maxi-K, by promoting K+ efflux to hyperpolarize the cell membrane and reducing Ca2+ influx. BMS-223131 can be used for the research of neurological disease, such as stroke[1].

275375-69-4

12352005

Cytochrome P450; Potassium Channel

Membrane Transporter/Ion Channel; Metabolic Enzyme/Protease

Neuroscience-Neuromodulation

Neurological Disease

O=C1NC2=C(C=C(C(F)(F)F)C=C2)C(C3=CC(Cl)=CC=C3O)=C1CCO

C18H13ClF3NO3

383.75

[1]Vrudhula VM, et al. Analogs of a potent maxi-K potassium channel opener with an improved inhibitory profile toward cytochrome P450 isozymes. Bioorg Med Chem Lett. 2005 Oct 1;15 (19) :4286-90.

Room temperature

http://file.medchemexpress.com/batch_PDF/HY-19397/

Reference compound1

Phase 2

CYP1A2; CYP2C19; CYP2C9; CYP2D6; CYP3A4